Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.54 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796577 | 0.93 | SLC6A2 (0.60) | SLC6A2NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL29836567 | 0.93 | SLC6A2 (0.60) | SLC6A2NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL31490020 | 0.90 | OPRM1 (0.59) | SLC6A2NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL29465926 | 0.90 | OPRM1 (0.59) | SLC6A2NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL29796546 | 0.89 | OPRM1 (0.56) | SLC6A2NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL31366734 | 0.89 | SLC6A2 (0.55) | SLC6A2NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL31020744 | 0.89 | SLC6A2 (0.63) | SLC6A2NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL29705074 | 0.89 | SLC6A2 (0.59) | SLC6A2NTSR1NTSR2CALCRLSORT1 | |
| SCHEMBL29966859 | 0.87 | SLC6A2 (0.56) | SLC6A2NMUR2NTSR1NTSR2CALCRL | |
| SCHEMBL29966124 | 0.87 | SLC6A2 (0.56) | SLC6A2NMUR2NTSR1NTSR2CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | disclosed |
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SPOREGEN LIMITED (GB) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SI, FABP2, CRY1 | SLC6A2 4013/4885NMUR2 2717/4885NMUR1 1939/4885 |
| US-12171734-B2 | Pathogenic bacteria | CLPP, CLPX, ANTXR2 | SLC6A2 3807/4885NMUR2 4300/4885NMUR1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.